Non-surgical Periodontal Treatment With Adjunctive Use of Lactoferrin Contained in Toothpaste and Mouthwash
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Emoform Glic Toothpaste, Emoform Glic Mouthwash.
- Who it may be relevant to
- Registry conditions: Periodontal Diseases. Basic parameters: 18 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Non-surgical Periodontal Treatment With Adjunctive Use of Lactoferrin Contained in Toothpaste and Mouthwash: Randomized Clinical Trial
Overview
The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients.
Detailed description
The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. Patients' enrollment will be conducted according to inclusion criteria.
At the first visit, periodontal parameters will be recorded: Plaque Index (PI), recession (R) Bleeding on Probing (BoP), modified Marginal Gingival Index (mMGI), Papillary Marginal Gingival (PMGI), Plaque Control Record ( PCR %), Approximal Plaque Index (API), Clinical Attachment loss (CAL) and Probing Pocket Depth (PPD).
Professional debridement will be conducted with piezoelectric instrumentation and air-flow administration with glycine powders.
Subsequently, patients will be randomly divided into two groups:
\- the Trial group, in which patients will perform home oral hygiene with Emoform Glic toothpaste + mouthwash twice a day the Control group, in which patients will perform home oral hygiene with Emoform Glic toothpaste twice a day.
Professional debridement will be repeated every 3 months. Periodontal indexes evaluation will be conducted at the baseline (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3).
Interventions
- Other Emoform Glic Toothpaste
Daily use of Emoform Glic toothpaste twice a day during home oral hygiene - Other Emoform Glic Mouthwash
Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
Primary outcome measures
- Change in Recession (R) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Plaque Index (Silness and Loe, 1964) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Bleeding on Probing (BoP) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Probing Pocket Depth (PPD) [Time frame: Baseline, 1, 3 and 6 months]
- Change in modified Marginal Gingival Index (mMGI) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Papillary Marginal Gingival Index (PMGI) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Plaque Control Record (PCR%) [Time frame: Baseline, 1, 3 and 6 months]
- Change in Clinical Attachment Loss (CAL) [Time frame: Baseline, 1, 3 and 6 months]
Eligibility criteria
Inclusion criteria
- women at the 4th month of pregnancy
Exclusion criteria
- presence of cardiac pacemaker
- neurological and psychiatric diseases
- patients taking bisphosphonates during the previous 12 months from the - beginning of the study
- patients undergoing anticancer therapy.
- patients with poor compliance.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Italy · 1 center
- Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnost — Pavia
Identifiers
NCT: NCT06311253 · 2024-LACTOFERRINPREGNANT